Chiesi Farmaceutici S.p.a.

Universita′ Degli Studi Di Milano

Marisa Pertile

Matteo Cerea

Micol Cirilli

Andrea Gazzaniga

Annamaria Soliani Raschini

Franco Sartor

The disclosure is directed to pharmaceutical compositions for oral administration comprising deferiprone. In particular, the disclosure is also directed to modified release tablets suitable either for twice daily administration or once daily administration. The disclosure is also directed to methods of making and using the same.

Modified release pharmaceutical formulations comprising deferiprone

The disclosure is directed to pharmaceutical compositions for oral administration in form of coated tablets that exhibit modified release properties when administered as either whole or half tablets. In particular, the disclosure is directed to modified release tablets comprising deferiprone, said tablets being suitable for twice daily oral administration. The disclosure is also directed to methods of making and using the same.

Physically and chemically stable pharmaceutical formulations in the form of an aqueous suspension comprising a reconstituted pulmonary surfactant are useful for the prophylaxis and/or treatment of respiratory distress syndrome (RDS) and other respiratory disorders.

Growing community of inventors

Parma, Italy

Marisa Pertile